Dry eye disease is something that affects up to 50 percent of the global population. Today’s guest leads a company that’s working on a cure for that and he’s here to discuss it.
Dave Bookbinder goes Behind The Numbers with Dr. Todd Brady, Chief Executive Officer at Aldeyra Therapeutics.
In this episode, Todd shares his journey from an Entrepreneur in Residence at a private equity firm to becoming a CEO of a publicly traded company. He also shares his ‘why’ behind the journey, which is rooted in helping society, and much more!
About the Host:
Dave Bookbinder is the person that clients reach out to when they need to know what their most important assets are worth.
Dave is a Managing Director at B. Riley Advisory Services, where he works closely with business owners, CFOs, Controllers, and CEOs. Dave has conducted valuations of the securities and intangible assets of public and private companies for various purposes.
Grab Dave’s best-selling book: The New ROI: Return on Individuals
Connect with Dave on LinkedIn
Connect with Dave on FaceBook
Follow Dave on Twitter
Check out NewROI.com for more.
💡 Want to share your insights with the business community? Message Dave to learn how you can be a guest on Behind The Numbers. https://linktr.ee/BehindTheNumbers
🔹 Check out more of Behind The Numbers on YouTube
🔹 Check out more of Behind The Numbers on RVN Television
Please share this podcast with your friends and subscribe to keep up with the latest episodes. Drop a review and rate the podcast so that others might find it.
THANK YOU FOR PUTTING BEHIND THE NUMBERS IN THE TOP 3% MOST POPULAR PROGRAMS GLOBALLY, ACCORDING TO LISTEN NOTES!!